| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Bone Marrow Transplant Program, Arizona Cancer Center [W. S. D., M. C. G.] and Department of Pathology [W. T. B., T. M. G.], University of Arizona School of Medicine, Tucson, Arizona 85724, and University of Michigan Cancer Center, Ann Arbor, Michigan 48109 [J. M. T.]
We present data describing a human myeloma cell line (8226/LR-5) selected for resistance to melphalan which exhibits a 7-fold level of resistance to melphalan and is partially cross-resistant to other bifunctional alkylators and X-irradiation. Melphalan resistance is relatively unstable with a decrease in resistance observed within 17 weeks in the absence of drug. The resistance observed in this cell line is not mediated by reduced intracellular melphalan accumulation. DNA interstrand cross-linking at equivalent intracellular drug accumulation is significantly reduced in the resistant subline. Whether this reduction is the result of a decrease in the formation of this lesion or to an increased rate of removal of the lesion remains to be determined. Growth characteristics and cell cycle kinetics, including S phase, were similar between sensitive and resistant cell lines. Intracellular nonprotein thiols were found to be significantly elevated in the resistant 8226/LR-5 cells; as cells revert or lose resistance, intracellular nonprotein sulfhydryl levels decline. Prior treatment of the cells with buthionine sulfoximine significantly reduced nonprotein sulfhydryl levels and enhanced melphalan cytotoxicity in both the sensitive and resistant cell lines. Thiols appear to play a role in mediating melphalan resistance.
1 This work was supported by National Cancer Institute Grant CA43043.
2 Preliminary results of this study were presented at the American Society of Clinical Oncology meeting, San Francisco, CA 1989 (48).
3 To whom requests for reprints should be addressed, at Bone Marrow Transplant Program, Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ 85724.
Received 5/ 4/90. Accepted 11/14/90.
This article has been cited by other articles:
|
|
 |
|
  M. B. Meads, L. A. Hazlehurst, and W. S. Dalton The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance Clin. Cancer Res., May 1, 2008; 14(9): 2519 - 2526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Trudel, Z. H. Li, J. Rauw, R. E. Tiedemann, X. Y. Wen, and A. K. Stewart Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma Blood, June 15, 2007; 109(12): 5430 - 5438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A. Lyu, L. H. Cheung, W. N. Hittelman, J. W. Marks, R. C.T. Aguiar, and M. G. Rosenblum The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA Mol. Cancer Ther., February 1, 2007; 6(2): 460 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Dalton and K. C. Anderson Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma. Clin. Cancer Res., November 15, 2006; 12(22): 6603 - 6610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Catley, E. Weisberg, T. Kiziltepe, Y.-T. Tai, T. Hideshima, P. Neri, P. Tassone, P. Atadja, D. Chauhan, N. C. Munshi, et al. Aggresome induction by proteasome inhibitor bortezomib and {alpha}-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood, November 15, 2006; 108(10): 3441 - 3449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fryknas, L. Rickardson, M. Wickstrom, S. Dhar, H. Lovborg, J. Gullbo, P. Nygren, M. G. Gustafsson, A. Isaksson, and R. Larsson Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model. J Biomol Screen, August 1, 2006; 11(5): 457 - 468. [Abstract] [PDF]
|
|
|
|
|
|
T. Stromberg, S. Ekman, L. Girnita, L. Y. Dimberg, O. Larsson, M. Axelson, J. Lennartsson, U. Hellman, K. Carlson, A. Osterborg, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells Blood, January 15, 2006; 107(2): 669 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Chen, P. C. Van der Sluis, D. Boulware, L. A. Hazlehurst, and W. S. Dalton The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells Blood, July 15, 2005; 106(2): 698 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Pei, Y. Dai, M. Rahmani, W. Li, P. Dent, and S. Grant The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01-Induced Apoptosis in Human Multiple Myeloma Cells Clin. Cancer Res., June 15, 2005; 11(12): 4589 - 4600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ghias, C. Ma, V. Gandhi, L. C. Platanias, N. L. Krett, and S. T. Rosen 8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: Role in induction of apoptosis in multiple myeloma Mol. Cancer Ther., April 1, 2005; 4(4): 569 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Krett, K. M. Davies, M. Ayres, C. Ma, C. Nabhan, V. Gandhi, and S. T. Rosen 8-Amino-adenosine is a potential therapeutic agent for multiple myeloma Mol. Cancer Ther., November 1, 2004; 3(11): 1411 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ikeda, Y. Nakata, F. Kimura, K. Sato, K. Anderson, K. Motoyoshi, M. Sporn, and D. Kufe Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid Mol. Cancer Ther., January 1, 2004; 3(1): 39 - 45. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. A. Hazlehurst, S. A. Enkemann, C. A. Beam, R. F. Argilagos, J. Painter, K. H. Shain, S. Saporta, D. Boulware, L. Moscinski, M. Alsina, et al. Genotypic and Phenotypic Comparisons of de Novo and Acquired Melphalan Resistance in an Isogenic Multiple Myeloma Cell Line Model Cancer Res., November 15, 2003; 63(22): 7900 - 7906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. McCafferty-Grad, N. J. Bahlis, N. Krett, T. M. Aguilar, I. Reis, K. P. Lee, and L. H. Boise Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells Mol. Cancer Ther., November 1, 2003; 2(11): 1155 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mitsiades, C. S. Mitsiades, P. G. Richardson, C. McMullan, V. Poulaki, G. Fanourakis, R. Schlossman, D. Chauhan, N. C. Munshi, T. Hideshima, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood, May 15, 2003; 101(10): 4055 - 4062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dai, T. H. Landowski, S. T. Rosen, P. Dent, and S. Grant Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism Blood, October 16, 2002; 100(9): 3333 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Grad, N. J. Bahlis, I. Reis, M. M. Oshiro, W. S. Dalton, and L. H. Boise Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells Blood, August 1, 2001; 98(3): 805 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-J. Vig Hjarnaa, E. Jonsson, S. Latini, S. Dhar, R. Larsson, E. Bramm, T. Skov, and L. Binderup CHS 828, a Novel Pyridyl Cyanoguanidine with Potent Antitumor Activity in Vitro and in Vivo Cancer Res., November 1, 1999; 59(22): 5751 - 5757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Damiano, A. E. Cress, L. A. Hazlehurst, A. A. Shtil, and W. S. Dalton Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines Blood, March 1, 1999; 93(5): 1658 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chesi, P. L. Bergsagel, O. O. Shonukan, M. L. Martelli, L. A. Brents, T. Chen, E. Schrock, T. Ried, and W. M. Kuehl Frequent Dysregulation of the c-maf Proto-Oncogene at 16q23 by Translocation to an Ig Locus in Multiple Myeloma Blood, June 15, 1998; 91(12): 4457 - 4463. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
